A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Skeletal-related Event-free Survival in Men With Bone Metastases From Prostate Cancer
Skeletal-related event free survival is the time from randomization until the first detected Skeletal Related Event (SRE). Patients who were still SRE-free at 18 months were censored.
18 months
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Australia: National Health and Medical Research Council
CZOL446E2432
NCT00242567
October 2005
January 2012
Name | Location |
---|